Federal Register / Vol. 87, No. 23 / Thursday, February 3, 2022 / Notices 6177 

Estimated Total Annual Burden 

Hours: 250,200. 

Authority: 45 CFR 75.203–75.204 and 

45 CFR part 75, Appendix I. 

Mary B. Jones, 

ACF/OPRE Certifying Officer. 

[FR Doc. 2022–02177 Filed 2–2–22; 8:45 am] 

BILLING CODE 4184–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Meetings of the Presidential Advisory 

Council on Combating AntibioticResistant Bacteria 

AGENCY: Department of Health and 

Human Services, Office of the Secretary, 

Office of the Assistant Secretary for 

Health. 

ACTION: Notice. 

SUMMARY: As stipulated by the Federal 

Advisory Committee Act, the 

Department of Health and Human 

Services (HHS) is hereby giving notice 

that a meeting is scheduled to be held 

for the Presidential Advisory Council on 

Combating Antibiotic-Resistant Bacteria 

(PACCARB). The meeting will be open 

to the public via Zoom and 

teleconference; a pre-registered public 

comment session will be held during 

the meeting. Pre-registration is required 

for members of the public who wish to 

present their comments at the meeting 

via Zoom/teleconference. Individuals 

who wish to send in their written public 

comment should send an email to 

CARB@hhs.gov. Registration 

information is available on the website 

http://www.hhs.gov/paccarb and must 

be completed by February 25, 2022 for 

the March 2, 2022 Public Meeting. 

Additional information about registering 

for the meeting and providing public 

comment can be obtained at http://

www.hhs.gov/paccarb on the Upcoming 

Meetings page. 

DATES: The meeting is scheduled to be 

held on March 2, 2022, from 10:00 a.m. 

to 4:00 p.m. ET (times are tentative and 

subject to change). The confirmed times 

and agenda items for the meeting will be 

posted on the website for the PACCARB 

at http://www.hhs.gov/paccarb when 

this information becomes available. Preregistration for attending the meeting is 

strongly suggested and should be 

completed no later than February 25, 

2022. 

ADDRESSES: Instructions regarding 

attending this meeting virtually will be 

posted at least one week prior to the 

meeting at: http://www.hhs.gov/ 

paccarb. 

FOR FURTHER INFORMATION CONTACT: 

Jomana Musmar, M.S., Ph.D., 

Designated Federal Officer, Presidential 

Advisory Council on Combating 

Antibiotic-Resistant Bacteria, Office of 

the Assistant Secretary for Health, U.S. 

Department of Health and Human 

Services, Room L616, Switzer Building, 

330 C St. SW, Washington, DC 20024. 

Phone: 202–746–1512; Email: CARB@

hhs.gov. 

SUPPLEMENTARY INFORMATION: The 

Presidential Advisory Council on 

Combating Antibiotic-Resistant Bacteria 

(PACCARB), established by Executive 

Order 13676, is continued by Section 

505 of Public Law 116–22, the 

Pandemic and All-Hazards 

Preparedness and Advancing Innovation 

Act of 2019 (PAHPAIA). Activities and 

duties of the Advisory Council are 

governed by the provisions of the 

Federal Advisory Committee Act 

(FACA), Public Law 92–463, as 

amended (5 U.S.C. App.), which sets 

forth standards for the formation and 

use of federal advisory committees. 

The PACCARB shall advise and 

provide information and 

recommendations to the Secretary 

regarding programs and policies 

intended to reduce or combat antibioticresistant bacteria that may present a 

public health threat and improve 

capabilities to prevent, diagnose, 

mitigate, or treat such resistance. The 

PACCARB shall function solely for 

advisory purposes. 

Such advice, information, and 

recommendations may be related to 

improving: The effectiveness of 

antibiotics; research and advanced 

research on, and the development of, 

improved and innovative methods for 

combating or reducing antibiotic 

resistance, including new treatments, 

rapid point-of-care diagnostics, 

alternatives to antibiotics, including 

alternatives to animal antibiotics, and 

antimicrobial stewardship activities; 

surveillance of antibiotic-resistant 

bacterial infections, including publicly 

available and up-to-date information on 

resistance to antibiotics; education for 

health care providers and the public 

with respect to up-to-date information 

on antibiotic resistance and ways to 

reduce or combat such resistance to 

antibiotics related to humans and 

animals; methods to prevent or reduce 

the transmission of antibiotic-resistant 

bacterial infections; including 

stewardship programs; and coordination 

with respect to international efforts in 

order to inform and advance the United 

States capabilities to combat antibiotic 

resistance. 

The March 2, 2022, public meeting 

will be dedicated to providing a One 

Health retrospective on past novel viral 

outbreaks and how they impacted 

antimicrobial use, resistance, and 

stewardship. The meeting agenda will 

be posted on the PACCARB website at 

http://www.hhs.gov/paccarb when it has 

been finalized. All agenda items are 

tentative and subject to change. 

Instructions regarding attending the 

meeting virtually will be posted at least 

one week prior to the meeting at: http:// 

www.hhs.gov/paccarb. 

Members of the public will have the 

opportunity to provide comments live 

during the March meeting by preregistering online at http://

www.hhs.gov/paccarb. Pre-registration 

is required for participation in this 

session with limited spots available. 

Written public comments can also be 

emailed to CARB@hhs.gov by midnight 

February 25, 2022, and should be 

limited to no more than one page. All 

public comments received prior to 

February 25, 2022, will be provided to 

the Advisory Council members. 

Additionally, companies and/or 

organizations involved in combating 

antibiotic resistance have an 

opportunity to present their work to 

members of the Advisory Council live 

during an Innovation Spotlight. Preregistration is required for participation, 

with limited spots available. All 

information regarding this session can 

also be found online at http://

www.hhs.gov/paccarb. 

Dated: January 27, 2022. 

Jomana F. Musmar, 

Designated Federal Officer, Presidential 

Advisory Council on Combating AntibioticResistant Bacteria, Office of the Assistant 

Secretary for Health. 

[FR Doc. 2022–02291 Filed 2–2–22; 8:45 am] 

BILLING CODE 4150–44–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Amended 

Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the Arthritis, Connective 

Tissue and Skin Study Section, 

February 17–18, 2022, 9:00 a.m. to 7:00 

p.m., which was published in the 

Federal Register on January 19, 2022, 

FR DOC 2022–00962, 87 FR 2878. 

This notice is being amended to 

change the meeting date from February 

17–18, 2022, 9:00 a.m. to 7:00 p.m. to 

February 16–18, 2022, 12:00 p.m. to 

7:00 p.m. The meeting place remains the 


khammond on DSKJM1Z7X2PROD with NOTICES
6178 Federal Register / Vol. 87, No. 23 / Thursday, February 3, 2022 / Notices 

same. The meeting is closed to the 

public. 

Dated: January 28, 2022. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–02201 Filed 2–2–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Therapeutic 

Development and Preclinical Studies. 

Date: March 3–4, 2022. 

Time: 9:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Richard D. Schneiderman, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4138, 

Bethesda, MD 20817, 301–402–3995, 

richard.schneiderman@nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR 20– 

117: Maximizing Investigators’ Research 

Award (MIRA) for Early Stage Investigators 

(R35—Clinical Trial Optional). 

Date: March 7–8, 2022. 

Time: 9:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Altaf Ahmad Dar, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, 415–254–1803, altaf.dar@nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: Innovative Immunology. 

Date: March 9, 2022. 

Time: 10:00 a.m. to 8:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Dayadevi Balappa Jirage, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6700B Rockledge Drive, Room 4422, 

Bethesda, MD 20892, (301) 867–5309, 

jiragedb@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Bioengineering, Surgery, 

Anesthesiology and Trauma. 

Date: March 9, 2022. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Donald Scott Wright, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5108, 

MSC 7854, Bethesda, MD 20892, (301) 435– 

8363, wrightds@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Electronic 

Nicotine Delivery Systems and Tobacco Use. 

Date: March 9, 2022. 

Time: 11:00 a.m. to 9:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Kimm Hamann, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4118A, 

MSC 7814, Bethesda, MD 20892, 301–435– 

5575, hamannkj@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Skeletal Muscle and Exercise 

Physiology. 

Date: March 9, 2022. 

Time: 11:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Carmen Bertoni, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 805B, 

Bethesda, MD 20892, (301) 867–5309, 

bertonic2@csr.nih.gov. 

Name of Committee: Infectious Diseases 

and Immunology B Integrated Review Group; 

Clinical Research and Field Studies of 

Infectious Diseases Study Section. 

Date: March 10–11, 2022. 

Time: 9:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Pauline Cupit, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institute of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, 301–827–3275, cupitcunninghpm@

mail.nih.gov. 

Name of Committee: Infectious Diseases 

and Immunology A Integrated Review Group; 

Innate Immunity and Inflammation Study 

Section. 

Date: March 10–11, 2022. 

Time: 9:30 a.m. to 6:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Shahrooz Vahedi, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 810G, 

Bethesda, MD 20892, (301) 496–9322, 

vahedis@mail.nih.gov. 

Name of Committee: Biological Chemistry 

and Macromolecular Biophysics Integrated 

Review Group; Maximizing Investigators’ 

Research Award B Study Section. 

Date: March 10–11, 2022. 

Time: 10:00 a.m. to 9:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Sudha Veeraraghavan, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4166, 

MSC 7846, Bethesda, MD 20892, (301) 827– 

5263, sudha.veeraraghavan@nih.gov. 

Name of Committee: Molecular, Cellular 

and Developmental Neuroscience Integrated 

Review Group; Cellular and Molecular 

Biology of Neurodegeneration Study Section. 

Date: March 10–11, 2022. 

Time: 10:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Laurent Taupenot, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4188, 

MSC 7850, Bethesda, MD 20892, 301–435– 

1203, laurent.taupenot@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: January 28, 2022. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–02199 Filed 2–2–22; 8:45 am] 

BILLING CODE 4140–01–P 


khammond on DSKJM1Z7X2PROD with NOTICES